TCGA-44-A47G-01A-21R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.570
- ALLOGRAFT_REJECTION+0.550
- INTERFERON_GAMMA_RESPONSE+0.550
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_ALPHA_RESPONSE+0.490
- COAGULATION+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- KRAS_SIGNALING_UP+0.450
- ANGIOGENESIS+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.610
- MYC_TARGETS_V1-0.590
- MYC_TARGETS_V2-0.590
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.530
- DNA_REPAIR-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MTORC1_SIGNALING-0.400
- PROTEIN_SECRETION-0.400
- CHOLESTEROL_HOMEOSTASIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.951 |
| 2 | sclcA055A_S52.txt | — | cohortMD2 | 0.948 |
| 3 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.948 |
| 4 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.947 |
| 5 | sclc55A_S50.txt | — | cohortMD2 | 0.943 |
| 6 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.937 |
| 7 | c5e09ad2-1f0b-4ea3-9565-a1664f1bb468 | — | — | 0.937 |
| 8 | MNG303 | — | — | 0.937 |
| 9 | MDT-AP-1152 | Med | Medulloblastoma | 0.936 |
| 10 | R232 | — | — | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |